Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00840606 · ClinicalTrials.gov registry record · Phase 1
Buspirone Hydrochloride 30mg Tablets, Fasting
A Phase 1 study, sponsored by Teva Pharmaceuticals USA.
- Completed
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
NCT00840606: Completed Phase 1 study, sponsored by Teva Pharmaceuticals USA.
NCT00840606 is a Phase 1 study that has completed, run by Teva Pharmaceuticals USA. The registered enrollment target is 70 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00840606, a Phase 1 study, has completed, sponsored by Teva Pharmaceuticals USA.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
Study Summary
This study will compare the relative bioavailability (rate and extent of absorption) of 30 mg Buspirone Hydrochloride Tablets by TEVA Pharmaceuticals Industries, Ltd. with that of 30 mg BUSPAR® Tablets by Bristol-Myers Squibb Company following a single oral dose (1 x 30 mg tablet) in healthy adult volunteers under fasting conditions.
Interventions
- DRUG BUSPAR® 30 mg Tablet
- DRUG Buspirone Hydrochloride 30 mg Tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2001-12 |
| Est. Completion | 2002-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00840606
The ClinicalTrials.gov registry entry for NCT00840606 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Pharmaceuticals USA, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BUSPAR® 30 mg Tablet is the first listed.
NCT00840606 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00840606 about?
NCT00840606 is a clinical study titled "Buspirone Hydrochloride 30mg Tablets, Fasting". This study will compare the relative bioavailability (rate and extent of absorption) of 30 mg Buspirone Hydrochloride Tablets by TEVA Pharmaceuticals Industries, Ltd. with that of 30 mg BUSPAR® Tablets by Bristol-Myers Squibb Company following a single oral dose (1 x 30 mg tablet) in healthy adult v...
What is the current status of trial NCT00840606?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2001-12. Estimated completion is 2002-04.
What interventions are being tested in trial NCT00840606?
The interventions under investigation include: BUSPAR® 30 mg Tablet (DRUG), Buspirone Hydrochloride 30 mg Tablet (DRUG).
Who is sponsoring clinical trial NCT00840606?
This trial is sponsored by Teva Pharmaceuticals USA, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.